All In Biotech

Drug Trial Radar · NCT03065062

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors

Last checked: Nov 19, 2026Latest source record: Feb 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

75

Planned (sponsor's estimate)

Start

Feb 28, 2017

Primary completion

Dec 31, 2026

Study completion Jan 31, 2027

Sponsor

Lead sponsor
Dana-Farber Cancer InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Pfizer
First posted
Feb 27, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research study is studying a combination of drugs as a possible treatment for cancer that might have a specific change in the phosphatidylinositol-3 phosphate (PI3K) pathway.

Conditions

  • Lung Cancer Squamous Cell
  • Solid Tumors
  • Head & Neck Cancer
  • Pancreatic Cancer

Interventions

  • PalbociclibDrug

    Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.

  • GedatolisibDrug

    Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose and Recommended Phase 2 DoseTime frame: 2 years
  2. Incidence of Treatment-Emergent Adverse EventsTime frame: 2 years

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Massachusetts General Hospital

    Boston, Massachusetts

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.